Is Dynamic Autocrine Insulin Signaling Possible? A Mathematical Model Predicts Picomolar Concentrations of Extracellular Monomeric Insulin within Human Pancreatic Islets

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Wang, Minghu ^a   Li, Jiaxu ^a   Lim, Gareth E ^b   Johnson, James D ^b  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIMER; GLUCOSE; INSULIN; INSULIN RECEPTOR; MONOMER;

ARTICLE; AUTOCRINE EFFECT; DISSOCIATION; EXTRACELLULAR SPACE; INSULIN RELEASE; MATHEMATICAL MODEL; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PREDICTION; SIMULATION;

ALGORITHMS; AUTOCRINE COMMUNICATION; EXTRACELLULAR FLUID; GLUCOSE; HUMANS; INSULIN; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; KINETICS; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION;

EID: 84879062083     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064860     Document Type: Article

References (58)

1. Johnson JD, Alejandro EU, (2008) Control of pancreatic beta-cell fate by insulin signaling: The sweet spot hypothesis, Cell Cycle. 7: 1343-1347.
2. Leibiger IB, Leibiger B, Berggren PO, (2008) Insulin signaling in the pancreatic beta-cell, Annu Rev Nutr. 28: 233-251.
3. Gunton JE, Kulkarni RN, Yim S, Okada T, Hawthorne WJ, et al. (2005) Loss of ARNT/HIF1beta Mediates Altered Gene Expression and Pancreatic-Islet Dysfunction in Human Type 2 Diabetes, Cell. 122: 337-349.
4. Kulkarni RN, Bruning JC, Winnay JN, Postic C, Magnuson MA, et al. (1999) Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes, Cell. 96: 329-339.
5. Kulkarni RN, Holzenberger M, Shih DQ, Ozcan U, Stoffel M, et al. (2002) Beta-cell-specific deletion of the Igf1 receptor leads to hyperinsulinemia and glucose intol-erance but does not alter beta-cell mass, Nat Genet. 31: 111-115.
6. Ueki K, Okada T, Hu J, Liew CW, Assmann A, et al. (2006) Total insulin and IGF-I resistance in pancreatic beta cells causes overt diabetes, Nat Genet. 38: 583-588.
7. Ueki K, Okada T, Ozcan U, Kulkarni R, (2003) Endogenous insulin-mediated signaling protects apoptosis induced by glucose in pancreatic beta-cells, Diabetes. 52: A42-A42.
8. Okada T, Liew CW, Hu J, Hinault C, Michael MD, et al. (2007) Insulin recep-tors in beta-cells are critical for islet compensatory growth response to insulin resistance, Proc Natl Acad Sci U S A. 104: 8977-8982.
9. Mehran AE, Templeman NM, Brigidi GS, Lim GE, Chu KY, et al. (2012) Hyperinsulinemia drives diet-induced obesity independently of brain insulin production, Cell Metabolism. 16: 723-737.
10. Li X, Zhang L, Meshinchi S, Dias-Leme C, Raffin D, et al. (2006) Islet mi-crovasculature in islet hyperplasia and failure in a model of type 2 diabetes, Diabetes. 55: 2965-2973.
11. Johnson JD, Misler S, (2002) Nicotinic acid-adenine dinucleotide phosphate-sensitive calcium stores initiate insulin signaling in human beta cells, Proc Natl Acad Sci U S A. 99: 14566-14571.
12. Alejandro EU, Kalynyak TB, Taghizadeh F, Gwiazda KS, Rawstron EK, et al. (2010) Acute insulin signaling in pancreatic beta-cells is mediated by multiple Raf-1 dependent pathways, Endocrinology. 151: 502-512.
13. Alejandro EU, Johnson JD, (2008) Inhibition of raf-1 alters multiple downstream pathways to induce pancreatic beta-cell apoptosis, Journal of Biological Chemistry. 283: 2407-2417.
14. Lim GE, Piske M, Johnson JD (2013), 14-3-3 proteins are essential signalling hubs for beta cell survival, Diabetologia.
15. Beith JL, Alejandro EU, Johnson JD, (2008) Insulin stimulates primary beta-cell proliferation via Raf-1 kinase, Endocrinology. 149: 2251-2260.
16. Bouche C, Lopez X, Fleischman A, Cypess AM, O'Shea S, et al. (2010) Insulin enhances glucose-stimulated insulin secretion in healthy humans, Proc Natl Acad Sci U S A. 107: 4770-4775.
17. Luciani DS, Johnson JD, (2005) Acute effects of insulin on beta-cells from trans-plantable human islets, Molecular and Cellular Endocrinology. 241: 88-98.
18. Johnson JD, Ford EL, Bernal-Mizrachi E, Kusser KL, Luciani DS, et al. (2006) Suppressed insulin signaling and increased apoptosis in CD38-null islets, Diabetes. 55: 2737-2746.
19. Song SH, McIntyre SS, Shah H, Veldhuis JD, Hayes PC, et al. (2000) Direct measurement of pulsatile insulin secretion from the portal vein in human subjects, J Clin Endocrinol Metab. 85: 4491-4499.
20. Saisho Y, Butler AE, Meier JJ, Monchamp T, Allen-Auerbach M, et al. (2007) Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type-2 diabetes, Clin Anat. 20: 933-942.
21. Nyman LR, Wells KS, Head WS, McCaughey M, Ford E, et al. (2008), Real-time, multidimensional in vivo imaging used to investigate blood ow in mouse pancreatic islets, J Clin Invest.
22. Michael DJ, Ritzel RA, Haataja L, Chow RH, (2006) Pancreatic beta-cells secrete insulin in fast- and slow-release forms, Diabetes. 55: 600-607.
23. Whittaker L, Hao C, Fu W, Whittaker J, (2008) High-a_nity insulin binding: insulin interacts with two receptor ligand binding sites, Biochemistry. 47: 12900-12909.
24. Li JX, Johnson JD, (2009) Mathematical Models of Subcutaneous Injection of Insulin Analogues: A Mini-Review, Discrete and Continuous Dynamical Systems-Series B. 12: 401-414.
25. Misler S, Barnett DW, Gillis KD, Pressel DM, (1992) Electrophysiology of Stimulus-Secretion Coupling in Human Beta-Cells, Diabetes. 41: 1221-1228.
26. Soeborg T, Rasmussen CH, Mosekilde E, Colding-Jorgensen M, (2009) Absorp-tion kinetics of insulin after subcutaneous administration, Eur J Pharm Sci. 36: 78-90.
27. Li J, Kuang Y, (2009) Systemically modeling the dynamics of plasma insulin in subcu-taneous injection of insulin analogues for type 1 diabetes, Math Biosci Eng. 6: 41-58.
28. Mosekilde E, Jensen KS, Binder C, Pramming S, Thorsteinsson B, (1989) Modeling absorption kinetics of subcutaneous injected soluble insulin, J Pharmacokinet Biopharm. 17: 67-87.
29. Johnson JD, Ahmed NT, Luciani DS, Han Z, Tran H, et al. (2003) Increased islet apoptosis in Pdx1+/- mice, J Clin Invest. 111: 1147-1160.
30. Cabrera O, Berman DM, Kenyon NS, Ricordi C, Berggren PO, et al. (2006) The unique cytoarchitecture of human pancreatic islets has implications for islet cell func-tion, Proceedings of the National Academy of Sciences of the United States of America. 103: 2334-2339.
31. Pisania A, Weir GC, O'Neil JJ, Omer A, Tchipashvili V, et al. (2010) Quan-titative analysis of cell composition and purity of human pancreatic islet preparations, Laboratory investigation; a journal of technical methods and pathology. 90: 1661-1675.
32. Trajanoski Z, Wach P, Kotanko P, Ott A, Skraba F, (1993) Pharmacokinetic model for the absorption of subcutaneously injected soluble insulin and monomeric insulin analogues, Biomed Tech (Berl). 38: 224-231.
33. Matthews DR, Rudenski AS, Burnett MA, Darling P, Turner RC, (1985) The half-life of endogenous insulin and C-peptide in man asseessed by somatostatin suppres-sion, Clinical Endocrinology. 23: 71-79.
34. Meier JJ, Butler AE, Saisho Y, Monchamp T, Galasso R, et al. (2008) Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans, Diabetes. 57: 1584-1594.
35. Lammert E, Gu G, McLaughlin M, Brown D, Brekken R, et al. (2003) Role of VEGF-A in vascularization of pancreatic islets, Curr Biol. 13: 1070-1074.
36. Miles KA, Hayball MP, Dixon AK, (1995) Measurement of human pancreatic per-fusion using dynamic computed tomography with perfusion imaging, The British journal of radiology. 68: 471-475.
37. Palumbo P, Panunzi S, De Gaetano A, (2007) Qualitative behavior of a family of delay-differential models of the glucose-insulin system, Discrete and Continuous Dynami-cal Systems-Series B. 7: 399-424.
38. Panunzi S, Palumbo P, De Gaetano A, (2007) A discrete Single Delay Model for the Intra-Venous Glucose Tolerance Test, Theor Biol Med Model. 4: 35.
39. Li J, Wang M, DeGaetano A, Palumbo P, Panunzi S, (2012) The range of time delay and the global stability of the equilibrium for an IVGTT model, Math Biosc. 235: 128-137.
40. Li JX, Kuang Y, Mason CC, (2006) Modeling the glucose-insulin regulatory system and ultradian insulin secretory oscillations with two explicit time delays, Journal of The-oretical Biology. 242: 722-735.
41. Sturis J, Polonsky KS, Mosekilde E, Vancauter E, (1991) Computer-Model for Mechanisms Underlying Ultradian Oscillations of Insulin and Glucose, American Journal of Physiology. 260: E801-E809.
42. Smith HL (1995), Monotone Dynamical Systems, an Introduction to the Theory of Com-petitive and Cooperative Systems.
43. Polonsky KS, Given BD, Hirsch L, Shapiro ET, Tillil H, et al. (1988) Quan-titative Study of Insulin Secretion and Clearance in Normal and Obese Subjects, Journal of Clinical Investigations. 81: 435-441.
44. Jones CN, Pei D, Staris P, Polonsky KS, Chen YD, et al. (1997) Alterations in the glucose-stimulated insulin secretory dose-response curve and in insulin clearance in nondiabetic insulin-resistant individuals, The Journal of clinical endocrinology and metabolism. 82: 1834-1838.
45. Tarin C, Teufel E, Pico J, Bondia J, Pfleiderer HJ, (2005) Comprehensive pharmacokinetic model of insulin Glargine and other insulin formulations, IEEE Trans Biomed Eng. 52: 1994-2005.
46. Engelborghs K, Lemaire V, Belair J, Roose D, (2001) Numerical bifurcation analysis of delay differential equations arising from physiological modeling, Journal of Mathematical Biology. 42: 361-385.
47. De Meyts P, Whittaker J, (2002) Structural biology of insulin and IGF1 receptors: implications for drug design, Nat Rev Drug Discov. 1: 769-783.
48. Kulkarni RN, (2005) New insights into the roles of insulin/IGF-I in the development and maintenance of beta-cell mass, Rev Endocr Metab Disord. 6: 199-210.
49. Horuk R, Blundell TL, Lazarus NR, Neville RW, Stone D, et al. (1980) A monomeric insulin from the porcupine (Hystrix cristata), an Old World hystricomorph, Nature. 286: 822-824.
50. Carroll RJ, Hammer RE, Chan SJ, Swift HH, Rubenstein AH, et al. (1988) A mutant human proinsulin is secreted from islets of Langerhans in increased amounts via an unregulated pathway, Proceedings of the National Academy of Sciences of the United States of America. 85: 8943-8947.
51. Lemaire K, Ravier MA, Schraenen A, Creemers JW, Van de Plas R, et al. (2009) Insulin crystallization depends on zinc transporter ZnT8 expression, but is not required for normal glucose homeostasis in mice, Proceedings of the National Academy of Sciences of the United States of America. 106: 14872-14877.
52. Horuk R, Goodwin P, O'Connor K, Neville RW, Lazarus NR, et al. (1979) Evolutionary change in the insulin receptors of hystricomorph rodents, Nature. 279: 439-440.
53. Ish-Shalom D, Christoffersen CT, Vorwerk P, Sacerdoti-Sierra N, Shymko RM, et al. (1997) Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor, Diabetologia. 40Suppl 2: S25-31.
54. Fisher WE, Boros LG, Schirmer WJ, (1996) Insulin promotes pancreatic cancer: evidence for endocrine inuence on exocrine pancreatic tumors, J Surg Res. 63: 310-313.
55. Gullo L, (1999) Diabetes and the risk of pancreatic cancer, Ann Oncol. 10Suppl 4: 79-81.
56. Evert M, Sun J, Pichler S, Slavova N, Schneider-Stock R, et al. (2004) Insulin receptor, insulin receptor substrate-1, Raf-1, and Mek-1 during hormonal hepato-carcinogenesis by intrahepatic pancreatic islet transplantation in diabetic rats, Cancer Res. 64: 8093-8100.
57. Currie CJ, Poole CD, Gale EA, (2009) The inuence of glucose-lowering therapies on cancer risk in type 2 diabetes, Diabetologia. 52: 1766-1777.
58. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL, (2009) Antidiabetic therapies affect risk of pancreatic cancer, Gastroenterology. 137: 482-488.